First-in-human,Phase 1/2 proof-of-concept clinical trial of topical product candidate SNA-125 in the treatment of psoriasis and the associated pruritus, or itch.
Phase of Trial: Phase I/II
Latest Information Update: 27 Aug 2018
At a glance
- Drugs SNA 125 (Primary)
- Indications Pruritus; Psoriasis
- Focus Adverse reactions; First in man; Proof of concept
- 27 Aug 2018 Results presented in a Sienna Biopharmaceuticals media release
- 14 Feb 2018 According to a Sienna Biopharmaceuticals media release, first patient has been dosed and expect to report top-line data in the third quarter of 2018
- 14 Feb 2018 Status changed from planning to recruiting.